Antibody-targeted superantigen C215Fab-SEA is a fusion protein of staphylococcal enterotoxin A (SEA) and the Fab region of the tumor-reactive C215 mAb. It can trigger CTL against C215 antigen-positive tumor cells and induce tumorsuppressive cytokines. However, the antitumor effect of C215Fab-SEA is not satisfactory because of suboptimal production of Th1 cytokines after repeated administration. Interleukin 18 (IL-18) is a novel cytokine with profound effects on Th1 cellular response. In this study, we showed that adenovirus-mediated intratumoral IL-18 gene transfer strongly improved the therapeutic efficacy of C215Fab-SEA in the pre-established C215 antigen-expressing B16 melanoma murine model. More significant tumor inhibition and
Introduction
The existence of T cell-specific tumor immunity has been demonstrated in several human malignancies, eg malignant melanoma and renal carcinoma. [1] [2] [3] The frequency of these tumor-specific T cells is generally too low to interfere with progressive tumor growth. Recruitment and activation of tumor-specific T lymphocytes is a major goal for immunotherapy of malignant tumors.
Superantigens (SAgs) are a collection of bacterial and viral proteins which bind to MHC class II molecules without the need for processing and subsequently activate a large number of T cells expressing particular T cell receptor (TCR) V␤-families. 4 The biologic functions of SAgs make them attractive to use for targeted T cell activation and elimination of tumor cells expressing MHC class II. Staphylococcal enterotoxin A (SEA) belonging to the family of bacterial SAgs is capable of activating a large number of T lymphocytes which possess various potential antitumor functions, such as perforin-mediated or Fas-FasL-induced apoptosis and secretion of growth suppressive cytokines. [5] [6] [7] However, MHC class II products are expressed on normal B cells and monocytes and only to a limited degree on most tumors. To develop a prolonged survival time were observed in tumor-bearing mice received combined therapy of C215Fab-SEA and Ad IL-18 than those of mice treated with C215Fab-SEA or AdIL-18 alone. Combination therapy augmented NK and CTL activities of tumor-bearing mice more markedly. The production of IL-2 and IFN-␥ also increased more significantly. More potent antitumor effect of combined therapy was observed in IL-10 KO mice with enhanced Th1 response. Our data demonstrated that the antitumor effect of C215Fab-SEA immunotherapy could be potentiated significantly by combination with intratumoral IL-18 gene transfer through more efficient activation of Th1 immune responses. Gene Therapy (2001) 8, 542-550.
tumor-specific superantigen for cancer therapy, SEA was genetically fused to the Fab region of C215 or C242 monoclonal antibody (mAb) which was specific for human colon carcinoma. 8 Recombinant fusion protein of the tumor-reactive mAb and SEA (Fab-SEA) expressed a 100-fold stronger affinity for the tumor antigen than MHC class II molecules. 9 In vitro and in vivo studies have shown that Fab-SEA could target cytotoxic T cells against MHC class II − tumor cells bearing the proper tumor antigen in the absence of obvious systemic side-effects, [10] [11] [12] [13] [14] [15] [16] [17] which demonstrated functional substitution of the MHC class II-dependent presentation of SEA with tumor specificity.
However, the antitumor effect of Fab-SEA is still hampered by some limitations. Targeting of superantigenicity evoked a pseudo-specific immune attack but not a very specific immune response against the tumor. 8 Furthermore, a state of hyporesponsiveness characterized by sub-optimal production of IFN-␥, IL-2 and marginal CTL activity was induced after repeated treatment with Fab-SEA. 18 This hyporesponsiveness state may due to the functional anergy and the ultimate death of a large number of the responding T cells, which directly limited the therapeutic efficacy, and long-term survival was noted only in a small fraction of the tumor-bearing animals. 18 How to circumvent these problems and enhance the antitumor effect of Fab-SEA immunotherapy more efficiently? Rosendahl et al 16 reported that antitumor effect of Fab-SEA immunotherapy was potentiated by co-administration of fusion protein of Fab and IL-2 (Fab-IL-2). Administration of Fab-IL-2 and Fab-SEA strongly augmented the production of IFN-␥, restored responsiveness of T cells and prolonged the immune response in vivo. IFN-␥ plays an important role in the innate immunity. It was demonstrated that IFN-␥ is an important mediator in the overall cytostatic antitumor response during Fab-SEA therapy. 16 The presence of IFN-␥ producing T lymphocytes is highly relevant to the therapeutic effect since the B16 melanoma is extremely sensitive to IFN-␥ in vitro. 19, 20 Based on these findings, we tried a new strategy using adenovirus-mediated interleukin 18 (IL-18) gene transfer to potentiate the antitumor effect of Fab-SEA immunotherapy.
IL-18 is a newly identified cytokine that mediates many important biological functions including induction of IFN-␥, enhancement of NK cell activity, stimulation of proliferation of activated T cells, regulation of FasLdependent apoptosis and promotion of Th1 response. [21] [22] [23] [24] IL-18 was shown to induce the immune defense against tumors in various animal models. [25] [26] [27] We hypothesized that transfection of IL-18 gene into the tumor may augment the production of tumor-suppressive cytokines (IFN-␥ and IL-2), rescue the CTL against the tumor cells, enhance NK cell activity, and thus profoundly potentiate Fab-SEA-based cancer immunotherapy.
In order to investigate the in vivo antitumor immune response elicited by C215Fab-SEA and intratumoral IL-18 gene transfer, in the present study, we used murine B16 melanoma cells transfected with the gene encoding for human colon carcinoma-associated C215 antigen as a model. A B16 cell clone stably expressing C215 antigen (B16-C215) was established which could be specifically recognized by C215Fab-SEA fusion protein and then was used for the following study. C57BL/6 IL-10 gene knock out (KO) 28 and wild-type C57BL/6 mice were inoculated with B16-C215 melanoma cells to observe the therapeutic effects of combination of C215Fab-SEA with adenovirusmediated intratumoral IL-18 gene transfer and their related mechanisms. Our data illustrated that combination therapy elicited more significant antitumor effects through efficient activation of Th1 immune responses.
Results
Establishment of murine melanoma cell clone expressing human colon carcinoma-associated C215 antigen The expression vector pKGE839 containing the GA733-2 cDNA (encoding the C215 antigen) 29 and the neomycinresistance gene was transfected into B16 melanoma cells. G418-resistant clones were harvested. The expression of C215 antigen was analyzed by FACS. A C215 highly expressing clone was selected from B16-C215 cell clones and used in the following experiments. The C215 antigen expression on B16-C215 cells was stable. The in vitro and in vivo growth pattern of B16-C215 cells was similar to that of the wild-type B16 cells (data not shown).
More potent inhibition of tumor growth in melanomabearing mice by combined therapy of C215Fab-SEA and Ad IL-18 The construction of adenoviral vector encoding murine IL-18 (Ad IL-18) was described previously by us. 30 The Figure 2a demonstrated that C215Fab-SEA or Ad IL-18 administration alone showed a marked inhibitory effect on tumor growth when compared with PBS, AdLacZ, C242Fab-SEA control groups (P Ͻ 0.01). Tumor inhibition in mice treated with C215Fab-SEA was more significant than that in mice treated with Ad IL-18 (P Ͻ 0.01). The inhibition of melanoma growth could be observed most significantly in mice after combined treatment with C215Fab-SEA/Ad IL-18 when compared with that in mice treated with C215Fab-SEA, Ad IL-18 alone, C215Fab-SEA/ AdLacZ, AdLacZ, C242Fab-SEA, or PBS (P Ͻ 0.01).
C57BL/6 IL-10 KO mice with enhanced Th1 response were used to investigate the roles of endogenous Th1, Th2 cytokines during C215Fab-SEA and Ad IL-18 therapy. The data in Figure 2b showed that tumor growth in IL-10 KO mice treated with C215Fab-SEA was sup- pressed more significantly than that in wild-type C57BL/6 mice (P Ͻ 0.01). Tumor growth in IL-10 KO mice receiving combination therapy of C215Fab-SEA/Ad IL-18 was completely inhibited. All mice were tumorfree.
Increased survival period of melanoma-bearing mice after combined therapy of C215Fab-SEA and Ad IL-18 Five mice in each group were observed for their survival period. The results in Figure 3a showed that tumor-bearing C57BL/6 mice treated with Ad IL-18, C215Fab-SEA, C215Fab-SEA/AdLacZ survived much longer than mice treated with PBS, AdLacZ, C242Fab-SEA (P Ͻ 0.01). Mice of the C215Fab-SEA-treated group survived longer than mice of the Ad IL-18-treated group (P Ͻ 0.01). The survival time was further prolonged in mice received combined therapy as compared with that in mice treated with Ad IL-18 or C215Fab-SEA alone (P Ͻ 0.01). As shown in Figure 3b , tumor-bearing IL-10 KO mice treated with C215Fab-SEA or C215Fab-SEA/Ad IL-18 survived significantly longer than tumor-bearing wild-type C57BL/6 mice that received the same therapy (P Ͻ 0.01). Four of five IL-10 KO mice treated with C215Fab-SEA survived more than 90 days, while only one of five wild-type C57BL/6 mice treated with C215Fab-SEA and two of five mice receiving combined therapy were tumor-free and lived more than 90 days. All of the tumor-bearing IL-10 KO mice that received combined therapy were found to be tumor-free and lived more than 90 days. These data, together with the above data about the tumor growth, suggested that combined therapy of C215Fab-SEA administration and IL-18 gene transfer could elicit a more potent antitumor effect in vivo if Th1 response was enhanced.
More massive infiltration of inflammatory cells into the tumor mass after combined therapy of C215Fab-SEA and Ad IL-18 Subcutaneous tumor nodules were taken from tumorbearing mice that had been killed 5 days after the last injection. Histological examination of tumor mass showed that the most obvious infiltration of inflammatory cells (neutrophils, lymphocytes, monocytes) was present inside and around the tumors of the tumor-bearing mice that received combined therapy of C215Fab-SEA and Ad IL-18. Inflammatory cell infiltration was markedly observed in mice treated with C215Fab-SEA or AdlacZ/C215Fab-SEA, whereas relatively less infiltration was present in the tumors of Ad IL-18-treated mice. However, little infiltration of inflammatory cells was found inside and around tumors of PBS, AdLacZ and C242Fab-SEA control groups (as shown in Table 1 ).
Induction of splenic NK activity after combined therapy of C215Fab-SEA and Ad IL-18 Splenocytes derived from the tumor-bearing mice that had been killed after various therapies were used in cytolytic assays against YAC-1 cells at effector:target (E:T) ratios of 25:1, 50:1, 100:1 by a 4-h 51 Cr released assay. It was demonstrated in Figure 4 that the NK activity of lymphocytes from the tumor-bearing mice was very low, but the NK activity increased significantly after the mice were treated with C215Fab-SEA or Ad IL-18 (P Ͻ 0.01). NK activity of Ad IL-18-treated mice was higher than that of C215Fab-SEA or AdLacZ/C215Fab-SEA-treated mice (P Ͻ 0.05). Lymphocytes from the mice that received C215Fab-SEA/AdIL-18 therapy showed the highest NK Gene Therapy activity when compared with lymphocytes from other groups (P Ͻ 0.01). There was no significant difference in NK activity between the IL-10 KO mice and wild-type C57BL/6 mice that received the same therapy. These data suggested that the augmentation of nonspecific immunity might be involved in the antitumor response of the combined therapy of C215Fab-SEA and Ad IL-18.
Augmentation of CTL activity after combined therapy of C215Fab-SEA and Ad IL-18 Lymphocytes isolated from tumor-bearing mice of different groups that had been killed were cocultured with inactivated B16-C215 (5000 rad) for 7 days in the presence of recombinant murine IL-2 (20 U/ml), then collected as CTL effector cells and B16-C215 melanoma cells were used as target cells. The CTL activity was determined at E:T ratios of 12.5:1, 25:1, 50:1 by a standard 4-h 51 Cr release assay. As shown in Figure 5 , splenic CTL activity of Ad IL-18, C215Fab-SEA or AdLacZ/C215Fab-SEAtreated mice increased significantly when compared with that of control groups (P Ͻ 0.05), and CTL activity of C215Fab-SEA or AdLacZ/C215Fab-SEA-treated mice was higher than that of Ad IL-18-treated mice (P Ͻ 0.05). The highest CTL activity was induced in mice treated with C215Fab-SEA/Ad IL-18 compared with that in mice of other groups (P Ͻ 0.01). IL-10 KO mice exhibited increased CTL activity than wild-type C57BL/6 mice that received the same therapy (P Ͻ 0.05). It suggested that tumor-specific immunity was induced most significantly by the combined therapy of IL-18 gene transfer and C215Fab-SEA, especially when Th1 response was enhanced.
Enhancement of cytokine production after combined therapy of C215Fab-SEA and Ad IL-18 The Th1 (IL-2, IFN-␥) and Th2 (IL-4, IL-10) cytokines secreted by splenocytes derived from tumor-bearing mice after various therapies were detected by ELISA kits. As shown in Figure 6 , the production of IL-2 and IFN-␥ from lymphocytes derived from mice treated with Ad IL-18, C215Fab-SEA or C215Fab-SEA/AdLacZ were significantly higher than those from control groups (P Ͻ 0.01). After combined treatment with C215Fab-SEA and Ad IL-18, the production of IL-2 and IFN-␥ in the mice increased to the highest levels when compared with those of the three groups above (P Ͻ 0.05). It was noted that the levels of IL-2 and IFN-␥ were more markedly elevated in IL-10 KO mice treated with C215Fab-SEA or C215Fab-SEA/Ad IL-18 than in wild-type C57BL/6 mice receiving the same therapy (P Ͻ 0.05). The production of IL-4 in the tumor-bearing C57BL/6 mice treated with C215Fab-SEA or Ad LacZ/C215Fab-SEA increased as compared with that of the mice treated with PBS, AdLacZ, C242Fab-SEA (P Ͻ 0.05). The level of IL-4 in mice treated with AdIL-18 alone decreased as compared with that in mice of the control groups (P Ͻ 0.05). The IL-4 level in mice treated with C215Fab-SEA/Ad IL-18 was lower than that in mice treated with C215Fab-SEA alone (P Ͻ 0.05). The production of IL-10 was not detectable in IL-10 KO mice. The level of IL-10 in the wild-type C57BL/6 mice treated with Ad IL-18 alone decreased as compared with that in mice of the control groups (P Ͻ 0.05), while the IL-10 level in C215Fab-SEA or C215Fab-SEA/AdLacZ-treated mice was higher than that in controls (P Ͻ 0.05). After the tumor-bearing C57BL/6 mice were treated with C215Fab-SEA/Ad IL-18, the production of IL-10 was down-regulated as compared with that in mice treated with C215Fab-SEA alone (P Ͻ 0.05). These data indicated that enhanced antitumor effect of Fab-SEA therapy may be related to the increased production of Th1 cytokines (IL-2, IFN-␥) and decreased production of Th2 cytokines (IL-4, IL-10).
Discussion
A variety of immunologic strategies have been used to elicit strong antitumor responses to cause regression of established tumors. [31] [32] [33] [34] [35] Studies have illustrated that Fab-SEA therapy induced recruitment of tumor-infiltrating lymphocytes (TILs), cytokine production and apoptosis of tumor cells in vitro and in vivo. [10] [11] [12] [13] [14] [15] [16] [17] However, the antitumor effect of C215Fab-SEA therapy is often not satisfactory, especially in pre-established tumors. In this study, it was shown that tumor growth in mice treated with C215Fab-SEA was significantly inhibited compared with that in control groups, but the antitumor effect was not strong enough; complete tumor remission was seen in only 20% of the treated mice. SEA activates the T cells which express particular T cell receptor V␤ chains but not tumor-specific T cells, so Fab-SEA evoked a pseudospecific immune attack but not a very specific antitumor immune response. Furthermore, a phase of immune exhaustion including failure to produce IL-2 and the tumor-suppressive cytokines IFN-␥ and TNF-␣ as well as failure to induce potent CTL activity followed after the Fab-SEA treatment. 18 This hyporesponsiveness directly limited the therapeutic efficacy of Fab-SEA immunotherapy. Hyporesponsive T cells have a defect in the activation of P21 ras following TCR occupancy, which translates to a down-regulation of the AP-1 transcription factor. Early studies have shown that SAg-induced IL-2 hyporesponsiveness in vivo correlates with down-regulation of the AP-1 and p50/p65 Rel transcription factors, suggesting an intrinsic defect in anergic T cells. Exogenous IL-2 has been demonstrated to restore responsiveness 36 Rosendahl et al 18 reported that antitumor effect of Fab-SEA immunotherapy was potentiated by Fab-IL-2 co-administration. Fab-SEA combined with Fab-IL-2 augmented the production of IFN-␥, restored the responsiveness of T cells, prolonged the immune response in vivo, so limiting the development of immunological hyporesponsiveness. The presence of IFN-␥-producing T lymphocytes is highly relevant to antitumor effect since the B16 melanoma is extremely sensitive to IFN-␥ in vitro. 20, 21 IL-18 is a newly discovered cytokine, structurally similar to IL-1, with profound effects on T cell activation. It plays an important role in the Th1 response, primarily by its ability to induce IFN-␥ production in T cells and NK cells and regulation of FasL-dependent apoptosis. 22 37 Intratumoral injection of a single dose of recombinant IL-18 substantially delayed the growth of subcutaneously inoculated gliomas. 27 IL-18 also acts as an angiogenesis suppressor in vitro and in vivo, sufficiently potent to suppress the fibroblast growth factor-induced corneal neovascularization and inhibit embryonic angiogenesis in the chick chorioallantoic membrane assay. 38 The biologic functions of IL-18 mentioned above make it attractive to be used in potentiating the antitumor effects of Fab-SEA.
In this study, we demonstrated that combination of intratumoral IL-18 gene transfer and C215Fab-SEA administration elicited antitumor immune response most potently. It might be a promising new approach for cancer immunogenetherapy. Inhibition of subcutaneous tumor growth was observed most significantly in mice after combined therapy of C215Fab-SEA and Ad IL-18 when compared with that in mice treated with Ad IL-18 or C215Fab-SEA alone. More inflammatory cells were present around and in the tumor mass after combined therapy. Spleen cells from mice that received combined therapy showed the highest CTL activity as compared with those from the mice treated with C215Fab-SEA, Ad IL-18 alone. NK activity is also efficiently induced after combined therapy, suggesting that augmentation of tumor-specific and nonspecific immunity both participated in the enhanced antitumor response induced by C215Fab-SEA and Ad IL-18 combined therapy. Therefore, combination of antibody-targeted superantigen and adenovirus-mediated IL-18 gene transfer might be a potential therapy to be utilized in cancer intervention.
In the murine immune system, CD4 + helper T cells can be distinguished into two types: 'Th1' cells that facilitate cell-mediated cytotoxicity by the secretion of IL-2, IFN-␥, TNF-␣ and 'Th2' cells that stimulate B cell growth, differentiation and antibody production by the production of IL-4, IL-5, IL-6, IL-10. To investigate the importance of Th1 and Th2 cytokines, antitumor effect of combined therapy in IL-10 KO mice was investigated in our study, but IFN-␥ receptor knockout mice were not used because
Gene Therapy no such kind of mice with the C57BL/6 background were available.
Tumor growth in IL-10 KO mice treated with C215Fab-SEA was suppressed more significantly and these mice survived significantly longer than wild-type C57BL/6 mice. All tumor-bearing IL-10 KO mice receiving combined therapy were tumor-free and survived more than 90 days, but only 40% of tumor-bearing C57BL/6 mice receiving combined therapy were tumor-free. The production of IL-2 and IFN-␥ from lymphocytes increased after the mice were treated with C215Fab-SEA, Ad IL-18 alone. The levels of IL-2 and IFN-␥ in mice with combined treatment were the highest compared with those of mice in other groups. The levels of IL-2 and IFN-␥ in IL-10 KO mice after treatment with C215Fab-SEA or C215Fab-SEA/Ad IL-18 were more markedly elevated than those in wild-type C57BL/6 mice. The level of IL-10 in the wild-type C57BL/6 mice treated with Ad IL-18 alone decreased as compared with that in mice of control groups, while the IL-10 level in C215Fab-SEA-treated mice was higher than that in controls. After being treated with C215Fab-SEA/Ad IL-18, the production of IL-10 in the tumor-bearing C57BL/6 mice decreased as compared with that in mice treated with C215Fab-SEA alone. These results suggested that Th1 cytokines (IL-2, IFN-␥) play important roles in Fab-SEA and IL-18 immunotherapy and in vivo expression of IL-18 can augment the Th1 responses and enhance the therapeutic effect of C215Fab-SEA targeted immunotherapy of cancer. The antitumor effect of Fab-SEA-based cancer immunotherapy could be impaired due to the release of the regulatory Th2-type cytokine IL-10. IL-10 has been known to down-regulate T cell immune responses by various mechanisms. It was shown to suppress both IFN-␥ production and the antitumor effector phase of IFN-␥. [39] [40] [41] It may inhibit and down-regulate MHC-II molecule expression of monocytes as well as interfere with antigen presentation, 42 inhibit the up-regulation of co-stimulatory molecules 43 and suppress the cytotoxicity of macrophages. 44 In addition, it was recently demonstrated that T cell receptor triggering in the presence of IL-10 inhibited IFN-␥ production in freshly isolated CD4 + T cells 45 and downregulated the expression of granzyme B. 40, 46 The production of IL-4 in the tumor-bearing C57BL/6 mice treated with C215Fab-SEA alone increased as compared with that of mice in control groups, while the level of IL-4 in mice treated with AdIL-18 alone was lower that in mice of control groups. After the combined treatment with C215Fab-SEA/Ad IL-18, the IL-4 level of tumorbearing C57BL/6 mice decreased as compared with that in mice treated with C215Fab-SEA alone. IL-4 may act as an immunoregulatory cytokine during C215Fab-SEA treatment and Ad IL-18 therapy may down-regulate the production of IL-4. The mechanism remains to be elucidated.
However, the direct role of SAgs in tumor development remains to be addressed. Bacterial SAgs are often used as immunostimulants for infection and tumor immunity because of their strong T cell stimulation activity. On the other hand, SAg from endogenous mouse mammary tumor virus (MMTV) functions as an immunogenic factor in tumor development. Masayuki U et al 47 reported that expression of viral SAg enhances the tumorigenicity of a myeloma cell line through the stimulation of SAg-reactive T cells. SAg expression from inherited provirus usually leads to depletion of immature T cells expressing reactive TCR ␤ chains during intrathymic T cell development. The characteristic of SAg for strong T cell stimulation is critical in successful infection of the mammary gland for exogenous MMTV and in skewing the T cell repertoire via clonal deletion for endogenous MMTV.
Materials and methods

Animals
Male or female wild-type C57BL/6 mice (H-2K b ), C57BL/6 IL-10 gene knockout mice (IL-10 KO), 6ෂ8 weeks of age, purchased from Joint Ventures Sipper BK Experimental Animal Co (Shanghai, China), were housed in a specific pathogen-free condition for all experiments.
Cell lines B16, a melanoma cell line derived from C57BL/6 mice, YAC-1, an NK-sensitive lymphoma cell line of A/S (H2a) origin, and 293, a continuous cell line derived from human embryonic kidney were obtained from American Type Culture Collection (ATCC) (Rockville, MD, USA), maintained in RPMI-1640 medium supplemented with penicillin 100 U/ml, streptomycin 100 g/ml, 2-mercaptoethanol 50 mmol/l and 10% fetal calf serum (FCS). All culture media were purchased from Gibco-BRL (Gaithersburg, MD, USA) and fetal calf serum (FCS) was provided by Shanghai Institute of Biological Products (Shanghai, China).
Reagents C215 and C242 mAbs, reacting with human colon cancer, were produced and provided by Active Biotech Research (Sweden). Recombinant fusion proteins of the Fab regions of C215, C242 mAb and the superantigen SEA (C215Fab-SEA, C242Fab-SEA) were constructed as described by Dohlsten et al 8 and kindly provided by Active Biotech Research (Lund, Sweden). The fusion protein was expressed in Escherichia coli K-12 UL635 (ara-14, xyl-7, ⌬ompT, T4 R ) and purified using a protein G sepharose column and fractions containing Fab-SEA were passed through a PD-10 column (Pharmacia LKB Biotechnology, Lund, Sweden).
The expressing vector pKGE839 containing the GA733-2 cDNA (encoding the C215 antigen) 29 and the neomycin resistance gene were also gifts from Active Biotech Research AB.
The murine IL-2, murine IFN-␥, murine IL-4, murine IL-10 were purchased from Endogen (Woburn, MA, USA). The murine IL-18 ELISA kit was purchased from R & D Systems (Minneapolis, MN, USA).
Transfection of B16 melanoma cells with cDNA encoding the C215 antigen The expression vector pKGE839 encoding the C215 antigen was transfected into B16 melanoma cells using lipofectamine (Gibco-BRL, Grand Island, NY, USA). After transfection, the B16 cells were selected in RPMI 1640 medium containing 800 g/ml G418 (Sigma, St Louis, MO, USA). G418-resistant clones were harvested and analyzed for C215 antigen expression. The C215 highly expressing clone 5.B7 was selected. The expression of C215 antigen was analyzed by FACS. The B16-C215 cells were incubated with an optimal concentration of mouse anti-human C215 monoclonal antibody (Active Biotech) for 30 min at 4°C followed by washing with cold PBS for three times. The cells were then incubated with FITCconjugated goat anti-mouse IgG followed by washing three times with PBS and resuspended in PBS containing 1% formaldehyde. Flow cytometry was analyzed on a FACScalibur flow cytometer (Becton Dickinson, San Jose, CA, USA).
Preparation of recombinant adenoviruses
Replication-defective recombinant adenoviruses AdLacZ harboring the ␤-galactosidase gene and Ad IL-18 harboring the murine IL-18 gene were constructed from human adenovirus serotype 5 using homologous recombination. The procedures were described previously by us. 30 The expression of these genes was driven by a CAG promoter. The recombinant adenoviruses were released from 293 cells by three freeze/thaw cycles and subsequently propagated with 293 cells. The titers of the adenoviral preparations were determined by plaque-forming assay on 293 cells. Briefly, serial 10-fold dilutions of adenovirus were added to 24-well plates (Corning, NY, USA), containing confluent 293 cell monolayers. After 48 h of incubation in a humidified atmosphere, the end point of 50% infectivity was determined according to cytopathic effect. The recombinant adenoviruses produced were diluted to a titer of 10 10 p.f.u./ml in PBS and stored at −70°C for experiments.
Immunotherapy with C215Fab-SEA in combination with IL-18 gene transfer C215 antigen-expressing B16 melanoma cells (B16-C215) were taken from continuous culture, washed three times and resuspended in PBS without FCS for inoculation into mice. C57BL/6 IL-10 KO and wild-type mice were inoculated s.c. with 1 × 10 5 B16-C215 cells in a back leg. Three days after tumor cell inoculation, the tumor-bearing C57BL/6 mice were divided into seven groups and were injected intratumorally with any of the following preparations: PBS, AdlacZ, C242Fab-SEA (non-related antibody control), C215Fab-SEA, Ad IL-18, AdlacZ in combination with C215Fab-SEA (C215Fab-SEA/Ad LacZ), Ad IL-18 in combination with C215Fab-SEA (C215Fab-SEA/Ad IL-18). Each group contained eight mice. Tumor-bearing IL-10 KO mice were divided into three groups and received therapy of the following preparations: PBS, C215Fab-SEA, C215Fab-SEA/Ad IL-18. Each group also contained eight IL-10 KO mice.
Three days after the tumor inoculation 10 8 p.f.u. virus/0.1 ml was injected intratumorally and a booster of the same dose was given after 8 days. From 4 days after the tumor inoculation, C215Fab-SEA 15 g per animal was injected intratumorally every other day for four times. The length and width of the tumor mass were measured with calibers every other day after tumor inoculation. Tumor size was expressed as 1/2 (length + width). Five mice in each group were observed for their survival period.
Determination of intratumoral IL-18 mRNA expression by semiquantitative RT-PCR One week after intratumoral injection with Ad IL-18, AdLacZ or PBS, total RNA was extracted from subcutaneous tumor tissues by TRIzol Reagent (Gibco-BRL), 549 according to the instructions of the manufacturer. One g total RNA from each sample was reverse transcribed using a Reverse Transcription System kit (MBI Fermentas, Vilnius, Lithuania) in a total volume of 20 l. cDNA as readout of the mRNA was quantified in a competitive PCR using specific primers for IL-18 and ␤-actin. Primers for IL-18 amplification were 5′-ACTGTA CAACCGCAGTAATACGC-3′ (sense) and 5′-AGTGAA CATTACAGATTTATCCC-3′ (anti-sense), with an expected PCR product of 434 bp. Primers for amplification of ␤-actin were 5′-TGGAATCCTGTGGCATCCAT GAAAC-3′ (sense) and 5′-TAAAACGCAGCTCAGTAA CAGTCCG-3′ (anti-sense), with an expected PCR product of 348 bp. Cycling conditions were 30 s of denaturation at 94°C, 30 s of annealing at 56°C, and 45 s of extension at 72°C during 25 cycles for ␤-actin and 30 cycles for IL-18.
PCR products of ␤-actin and IL-18 were visualized by electrophoresis in a 1.5% agarose gel containing 0.5 g/ml ethidium bromide. Densities of the amplified ␤-actin and IL-18 were analyzed using the Kodak EDAS120 digital imaging system version 3 (Gibco). Results were expressed as a ratio of quantified IL-18 product over ␤-actin product.
Histologic examination
Subcutaneous tumor nodules were taken from dead tumor-bearing mice 5 days after the last injection. The tumor samples were fixed in 10% formalin solution, dehydrated and embedded in paraffin. Thin-sliced sections were stained with hematoxylin and eosin. The evaluation of tumor necrosis was: −, no necrosis; +, less than 1/3 of the tumor size; ++, 1/3ෂ2/3 of the tumor size; +++, more than 2/3 of the tumor size. The evaluation of the infiltration of inflammatory cell both in and around the tumor was: −, no inflammatory cell infiltration; +, minimal inflammatory cell infiltration; ++, medium inflammatory cell infiltration; +++, intense inflammatory cell infiltration.
Cytotoxic assay of CTL and NK cells Splenic lymphocytes were isolated from dead tumorbearing mice 5 days after the last injection. The erythrocytes were depleted with 0.83% ammonium chloride and macrophages were removed by adherence of splenocytes on plastic plates for 2 h. The non-adherent lymphocytes were directly used as NK effector cells. The lymphocytes were cocultured with inactivated B16-C215 (5000 rad) for 7 days in the presence of recombinant murine IL-2 (20 U/ml) and then collected as CTL effector cells. The NK activity and CTL activity were determined by a standard 4-h 51 Cr release assay as described in our previous work. 48 
Cytokine release assay
The non-adherent splenocytes derived from dead tumorbearing mice at a concentration of 1 × 10 7 cells/ml were stimulated with 1 × 10 6 irradiated B16-C215 (5000 rad). Supernatants were harvested after 24 h (for IL-2 assay), 48 h (for IL-4 and IL-10 assay), or 72 h (for IFN-␥ assay). The supernatants of B16-C215 cells at a concentration of 1 × 10 6 cells/ml after Ad IL-18 transfection were harvested at different times to detect the production of IL-18. The cytokines were measured using a standard sandwich ELISA technique with corresponding kits.
Statistics
All the experiments were run in triplicate and the results are means ± s.d. of triplicate determinations (or representation data from one or two independent experiments). Statistical analysis was performed using the Student's t test and log-rank test (for survival analysis). The difference was considered statistically significant when the P value was less than 0.05.
